Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00417872 · ClinicalTrials.gov registry record · Phase 2
Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis
A Phase 2 study of Clostridium Difficile, sponsored by Romark Laboratories L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
- 7
- Study locations
NCT00417872 is a Phase 2 study of Clostridium Difficile that has completed, run by Romark Laboratories L.C.. The registered enrollment target is 114 participants, below the 442-participant average among 6 other Clostridium Difficile trials with a reported enrollment target (74% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT00417872, a Phase 2 study of Clostridium Difficile, has completed, sponsored by Romark Laboratories L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary objective is to demonstrate non-inferiority of nitazoxanide administered 500 mg b.i.d compared to metronidazole administered 250 mg q.i.d. in resolving symptoms of Clotridium difficile colitis after seven days of treatment. Secondary objectives are to provide information on the times from first dose to last unformed stool and resolution of symptoms of colitis, the sustained response rates for the different tratment groups and the effect of treatment on Clostridium difficile toxin enzyme immunoassay/culture results during hospitalization.
Conditions Studied
Interventions
- DRUG Metronidazole
- DRUG Nitazoxanide
Study Locations (7)
Pennsylvania
- Lehigh Valley Hospital - Allentown
- The Reading Hospital and Medical Center - West Reading
Texas
- Houston Veterans Affairs Hospital - Houston
- St. Luke's Episcopal Hospital - Houston
Florida
- Bayfront Medical Center and Edward White Hospital - St. Petersburg
Georgia
- WellStar Infectious Diseases - Marietta
Ohio
- Remington-Davis, Inc., and Riverside Infection Consultants, Inc. - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00417872
The ClinicalTrials.gov registry entry for NCT00417872 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 442-participant average among 6 other Clostridium Difficile trials with a reported enrollment target (74% lower). The listed sponsor is Romark Laboratories L.C., which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clostridium Difficile appearing as the primary indexed condition, and to 2 interventions - of which Metronidazole is the first listed.
NCT00417872 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Pennsylvania, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT00417872 about?
NCT00417872 is a clinical study titled "Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis". The primary objective is to demonstrate non-inferiority of nitazoxanide administered 500 mg b.i.d compared to metronidazole administered 250 mg q.i.d. in resolving symptoms of Clotridium difficile colitis after seven days of treatment. Secondary objectives are to provide information on the times fro...
What is the current status of trial NCT00417872?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2004-01. Estimated completion is 2005-09.
What conditions does trial NCT00417872 study?
This clinical trial studies the following conditions: Clostridium Difficile.
What interventions are being tested in trial NCT00417872?
The interventions under investigation include: Metronidazole (DRUG), Nitazoxanide (DRUG).
Who is sponsoring clinical trial NCT00417872?
This trial is sponsored by Romark Laboratories L.C., which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00417872 being conducted?
This trial has 7 study locations across Florida, Georgia, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
COMPLETED · Phase 2
-
Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study
COMPLETED · Phase 2
-
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
RECRUITING · Phase 3
-
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
RECRUITING
-
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
ACTIVE NOT RECRUITING
-
Early FMT for C.Difficile
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.